BIOMARIN PHARMACEUTICAL INC
Form 4
April 02, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *
KAKKIS EMIL D

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/01/2008(1)	04/01/2008	M		18,000	A	$ 4	104,164	D	
Common Stock	04/01/2008(1)	04/01/2008	S		700	D	$ 35.6825	103,464	D	
Common Stock	04/01/2008(1)	04/01/2008	S		100	D	$ 35.724	103,364	D	
Common Stock	04/01/2008(1)	04/01/2008	S		700	D	$ 35.655	102,664	D	
	04/01/2008(1)	04/01/2008	S		200	D		102,464	D	

Common Stock						$ 35.6483		
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.6817	102,264	D
Common Stock	04/01/2008(1)	04/01/2008	S	100	D	$ 35.6925	102,164	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7049	101,964	D
Common Stock	04/01/2008(1)	04/01/2008	S	100	D	$ 35.69	101,864	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.687	101,664	D
Common Stock	04/01/2008(1)	04/01/2008	S	800	D	$ 35.7075	100,864	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7101	100,664	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7042	100,464	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7317	100,264	D
Common Stock	04/01/2008(1)	04/01/2008	S	300	D	$ 35.68	99,964	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7	99,764	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.66	99,564	D
Common Stock	04/01/2008(1)	04/01/2008	S	300	D	$ 35.65	99,264	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.6781	99,064	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.667	98,864	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 35.7033	98,664	D
Common Stock	04/01/2008(1)	04/01/2008	S	100	D	$ 35.7975	98,564	D
Common Stock	04/01/2008(1)	04/01/2008	S	670	D	$ 35.78	97,894	D
Common Stock	04/01/2008(1)	04/01/2008	S	30	D	$ 35.74	97,864	D
	04/01/2008(1)	04/01/2008	S	200	D		97,664	D

Common Stock						$ 35.7631		
Common Stock	04/01/2008(1)	04/01/2008	S	250	D	$ 35.84	97,414	D
Common Stock	04/01/2008(1)	04/01/2008	S	550	D	$ 35.83	96,864	D
Common Stock	04/01/2008(1)	04/01/2008	S	200	D	$ 36.087	96,664	D
Common Stock	04/01/2008(1)	04/01/2008	S	537	D	$ 36.08	96,127	D
Common Stock	04/01/2008(1)	04/01/2008	S	106	D	$ 36.01	96,021	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	$ 4	04/01/2008(1)	04/01/2008	M			18,000	06/24/1998(2)	06/21/2008	Common Stock	18,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			Chief Medical Officer	

Signatures

/s/ G. Eric Davis, Attorney-in-Fact	04/01/2008
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.

(2) Original option grant vested 6/48ths on 12/24/1998 and 1/48th on the 24th of every month thereafter.

(3) Number of derivative securities amended to reflect options that expired unexercised during a prior year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.